Healthcare Equipment and Supplies
Company Overview of Harvest Technologies Corporation
Harvest Technologies Corporation provides bone marrow aspirate concentrate (BMAC) systems to treat vascular, orthopedic, and cardiovascular diseases. It offers SmartPReP 2 APC+, a technology platform for the rapid preparation of autologous platelet concentrate; and SmartPReP 2 BMAC, a point-of-care tool that provides orthopedic surgeons access to the healing potential of autologous stem cells. The company also provides hardware systems, such as SMP-2, a SmartPReP 2 platelet concentrate system; WS-2, a SmartPReP2 BMAC workstation; BW-60, a reusable counter balance weight for SmartPReP 2; and BMAC and SmartPReP 2 BMAC procedure packs, and BMAC bone graft applicators. In addition, it offers Sma...
40 Grissom Road
Plymouth, MA 02360
Founded in 1995
Key Executives for Harvest Technologies Corporation
Vice President of Operations
Vice President and General Manager of Strategic Business Development
Compensation as of Fiscal Year 2013.
Harvest Technologies Corporation Key Developments
Harvest Technologies Corporation Grants CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia
Nov 19 12
Harvest Technologies Corporation announced CE Marking for an expanded clinical indication for its SmartPReP(R) 2 Bone Marrow Aspiration Concentration System (BMAC(R) 2) product. The British Standards Institution (BSI), a notified body under the Medical Device Directive, has awarded a certificate indicating that the Harvest SmartPReP2 Bone Marrow Aspiration Concentrate System (BMAC2) is intended to be used at point-of-care for the safe and rapid preparation of autologous nucleated cell concentrate from Bone Marrow Aspiration (BMA) for administration into ischemic tissues of the affected limb due to No-Option Critical Limb Ischemia. This is the first time an autologous point-of-care cellular therapy company has presented sufficient clinical evidence for a notified body to grant approval to promote a specific product for this clinical use. This certification comes after BSI's extensive review of clinical data from nearly 50 clinical trials and investigations, including data using Harvest Technologies BMAC2 System. Previous studies have shown that critical limb ischemia (CLI) patients that have tissue loss (gangrenous or ulcer wounds) are at severe risk for amputation. Harvest studies have shown that the use of the BMAC2 system reduces that risk and is a viable option for limb salvage. The Harvest studies have also been able to show improvement in rest pain for patients with severe rest pain.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries